Allogeneic HCT using matched unrelated donors, mismatched unrelated donors, and umbilical cord blood (UCB) have comparable survival in patients with lymphoma, according to a large-scale analysis of 1,593 transplants between 2000 and 2010 reported to CIBMTR (Center for International Blood and Marrow Transplant Research). At a median follow-up of 55 months, 3-year adjusted survival was comparable: 43%, 37%, and 41% for transplants using 8/8 allele HLA-matched unrelated donors, 7/8 allele HLA-mismatched unrelated donors, and 4/6 or greater HLA-matched UCB (one or two units), respectively. The authors concluded that patients with lymphoma have acceptable survival after alternative donor transplantation and that mismatched unrelated donor and UBC transplants “can extend the curative potential of allotransplant to patients who lack a suitable HLA-matched sibling or matched unrelated donor.”
Bachanova V, et al. Bone Marrow Transplant
Patient-level summary of this study